133 related articles for article (PubMed ID: 37952982)
1. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi F; Döhner H; Wei AH; Montesinos P; Pfeilstöcker M; Papayannidis C; Lai Y; Wang K; See WL; de Menezes DL; Petrlik E; Prebet T; Roboz GJ
Br J Haematol; 2024 Mar; 204(3):877-886. PubMed ID: 37952982
[TBL] [Abstract][Full Text] [Related]
2. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
[TBL] [Abstract][Full Text] [Related]
3. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H; Wei AH; Roboz GJ; Montesinos P; Thol FR; Ravandi F; Dombret H; Porkka K; Sandhu I; Skikne B; See WL; Ugidos M; Risueño A; Chan ET; Thakurta A; Beach CL; Lopes de Menezes D
Blood; 2022 Oct; 140(15):1674-1685. PubMed ID: 35960871
[TBL] [Abstract][Full Text] [Related]
5. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
[TBL] [Abstract][Full Text] [Related]
6. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
[TBL] [Abstract][Full Text] [Related]
7. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
[TBL] [Abstract][Full Text] [Related]
8. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Roboz GJ; Ravandi F; Wei AH; Dombret H; Thol F; Voso MT; Schuh AC; Porkka K; La Torre I; Skikne B; Zhong J; Beach CL; Risueño A; Menezes DL; Ossenkoppele G; Döhner H
Blood; 2022 Apr; 139(14):2145-2155. PubMed ID: 34995344
[TBL] [Abstract][Full Text] [Related]
9. Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia.
Tabah A; Huggar D; Wang ST; Johnson SJ; Copher RM; O'Connell T; McBride A; LeBlanc TW
Future Oncol; 2022 Dec; ():. PubMed ID: 36507931
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Zheng F; Li Q; Yang S; Zhou Z; Zeng Q; Liu K
Hematology; 2023 Dec; 28(1):2276550. PubMed ID: 37916643
[TBL] [Abstract][Full Text] [Related]
14. Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia.
Tamura A; Ishida T; Saito A; Yamamoto N; Yokoi T; Uemura S; Nino N; Fujiwara T; Tahara T; Nakamura S; Kozaki A; Kishimoto K; Hasegawa D; Kosaka Y
Pediatr Blood Cancer; 2018 Oct; 65(10):e27284. PubMed ID: 29893458
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
17. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
[TBL] [Abstract][Full Text] [Related]
19. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
Zeidan AM; Pollyea DA; Borate U; Vasconcelos A; Potluri R; Rotter D; Kiendrebeogo Z; Gaugler L; Prebet T; Strocchia M; Bonifacio G; Chen C
Ann Hematol; 2023 Apr; 102(4):749-754. PubMed ID: 36732419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
